What is SiSaf?
SiSaf Ltd is a biopharmaceutical company headquartered in Guildford, England, dedicated to advancing RNA therapeutics for challenging conditions such as cancer and musculoskeletal disorders. The company's core innovation lies in its proprietary Bio-Courier technology, a sophisticated system that merges bioabsorbable silicon with organic materials. This unique approach is engineered to optimize the delivery of nucleic acids, thereby enhancing the efficacy of therapeutic agents. SiSaf is actively cultivating a pipeline of novel treatments, with a particular focus on therapies targeting pancreatic cancer, metastatic cancer, and osteopetrosis. Their operations are supported by state-of-the-art research and manufacturing facilities, positioning them at the forefront of biopharmaceutical innovation.
How much funding has SiSaf raised?
SiSaf has raised a total of $16.7M across 2 funding rounds:
Series A
$3.5M
Series B
$13.2M
Series A (2016): $3.5M with participation from Vickers Venture Partners and Exen Capital
Series B (2020): $13.2M led by Future Fund and Vickers Venture Partners
Key Investors in SiSaf
Future Fund
Future Fund, established in 2006, is an Australian investment fund focused on long-term growth and managing superannuation liabilities. While its primary focus is on Australian assets, its participation in SiSaf's Series B round suggests an interest in innovative global ventures.
Vickers Venture Partners
Vickers Venture Partners is a global venture capital firm with a strong focus on deep technology investments worldwide. With a history of backing successful companies, their investment in SiSaf highlights a strategic interest in cutting-edge biopharmaceutical technologies and delivery systems.
Exen Capital
Exen Capital operates with a focus on strategic investments, including venture capital and private equity, across international markets. Their involvement in SiSaf's Series A funding indicates a commitment to supporting companies with high-growth potential in the life sciences sector.
What's next for SiSaf?
The recent major strategic investment in SiSaf signals a pivotal moment for the company, likely enabling accelerated development of its RNA therapeutic pipeline. This influx of capital is expected to fuel further research, clinical trials, and potentially the scaling of manufacturing capabilities for their Bio-Courier technology. As SiSaf progresses through its development stages, this backing will be crucial for navigating the complex regulatory landscape and bringing their innovative treatments for cancer and musculoskeletal disorders to market. The company's focus on enhancing nucleic acid delivery positions it as a key player in the evolving field of targeted therapeutics.
See full SiSaf company page
